

## **Appendix**

### **Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies**

Samantha Tomicki, MPH; Gabriela Dieguez, FSA, MAAA; Helen Latimer, MPH; Paul Cockrum, PharmD; George Kim, MD

This Appendix is provided unedited as supplemental materials for this article, which was published in *American Health & Drug Benefits* in June 2021.

## Appendix A: Code Sets

### CODE SETS

<b>Diagnostic Category</b>	<b>ICD-9/10 Codes</b>
Pancreatic cancer diagnosis codes	ICD-9-CM 157.xx or ICD-10 C25.xx, excluding C25.4
Metastasis diagnosis codes	ICD-9-CM 196.xx, 197.xx, 198.xx, 199.0, 199.1 or ICD-10 C77.xx, C78.xx, C79.xx, C80.0, C80.1
Non-pancreatic primary or secondary malignancy codes	ICD-9-CM 140.xx-209.xx or ICD-10-CM C00.xx-C96.xx, C7A, C7B

## Appendix B: Exclusions

### EXCLUSIONS

- 2014-2017 Medicare Linked A, B, D data files
  - Patients with end stage renal disease (ESRD) were excluded from this analysis
  - Patients under 18
  - Patients with missing age or gender
  - Patients with evidence of certain non-pancreatic primary or secondary malignancy the 6-month pre-index period
- 2014-2018 MarketScan® data files
  - Patients with end stage renal disease (ESRD) were excluded from this analysis
  - Patients under 18 or over 65
  - Patients with missing age or gender
  - Patients with evidence of certain non-pancreatic primary or secondary malignancy the 3-month pre-index period

### LOT SUBSTITUTIONS

These events did not trigger a new LOT:

- Substituting fluorouracil for capecitabine or vice-versa did not advance the LOT

- Substituting leucovorin for levoleucovorin or vice-versa did not advance the LOT
- Adding leucovorin or levoleucovorin to a regimen did not advance the LOT
- Adding Abraxane (nab-paclitaxel) to a gemcitabine regimen or vice versa within 90 days of the start of the LOT did not advance the LOT, and both drugs were included in the regimen name

## Appendix C: Chemotherapies and Other Related Drugs

### THERAPIES OF INTEREST

The following chemotherapies and other drugs of interest were used in our line of therapy (LOT) logic:

- 5-FU (5-fluorouracil)
- FOLFIRINOX (5-FU, leucovorin, oxaliplatin, irinotecan)
- FOLFOX (5-FU, leucovorin, oxaliplatin)
- FOLFIRI (5-FU, leucovorin, irinotecan)
- Capecitabine
- Gemcitabine
- Gemcitabine/nab-paclitaxel
- Gemcitabine plus Other
- 5-FU plus leucovorin plus liposomal irinotecan
- Liposomal irinotecan plus any non-5-FU-agent
- Oxaliplatin plus docetaxel
- Oxaliplatin plus irinotecan
- Nab-paclitaxel
- Irinotecan
- Docetaxel
- Cisplatin
- Oxaliplatin
- Erlotinib
- Pembrolizumab